This article has Open Peer Review reports available.
The triterpenoids of Hibiscus syriacus induce apoptosis and inhibit cell migration in breast cancer cells
- Ren-Jun Hsu†1, 2,
- Yao-Chin Hsu†3,
- Shu-Pin Chen†4,
- Chia-Lynn Fu1,
- Jyh-Cherng Yu5,
- Fung-Wei Chang6,
- Ying-Hsin Chen7,
- Jui-Ming Liu8,
- Jar-Yi Ho1, 9Email author and
- Cheng-Ping Yu1, 9Email author
© Hsu et al.; licensee BioMed Central. 2015
Received: 1 October 2014
Accepted: 26 February 2015
Published: 14 March 2015
Breast cancer-related mortality increases annually. The efficacy of current breast cancer treatments is limited, and they have numerous side effects and permit high recurrence. Patients with estrogen receptor (ER)-negative or triple-negative breast cancer are particularly difficult to treat. Treatment for this type of cancer is lacking, and its prognosis is poor, necessitating the search for alternative treatments.
This study screened Chinese herb Hibiscus syriacus extracts and identified a novel anti-cancer drug for patients with ER-negative breast cancer. The inhibitory effects on cell viability and migration were evaluated for each compound, and the molecular regulatory effects were evaluated on both mRNA and protein levels.
We found several triterpenoids including betulin (K02) and its derivatives (K03, K04, and K06) from H. syriacus inhibited human triple-negative breast cancer cell viability and migration but revealed smaller cytotoxic effects on normal mammalian epithelial cells. Betulin and its derivatives induced apoptosis by activating apoptosis-related genes. In addition, they activated p21 expression, which induced cell cycle arrest in breast cancer cells. Betulin (K02) and betulinic acid (K06) had stronger inhibitory effects on cell viability and migration than K03 and K04.
H. syriacus extracts might inhibit breast cancer cell viability and induce apoptosis by activating p53 family regulated pathways and inhibiting AKT activation. H. syriacus extracts may provide important insight into the development of novel alternative therapies for breast cancer.
Breast cancer is one of the most common cancers in females worldwide. Approximately 500,000 people die annually from breast cancer, and about one out of eight females are diagnosed with breast cancer . Currently, the main treatment for breast cancer is surgery, along with radiotherapy, chemotherapy, hormone, and immunological treatment. The efficacy of current treatments for breast cancer is limited. In addition to side effects, the risk of recurrence is high. Clinically, 70% of breast cancer patients are positive for the estrogen receptor (ER) in the tumor. After treatment with tamoxifen, the death rate and recurrence rate is reduced by 50% and 25%–30%, respectively. However, one-third of patients showed recurrence within fifteen years after tamoxifen treatment, and the cancer cells’ failure to express estrogen receptor (ER) is one of the most important reasons . Furthermore, 10%–15% of breast cancers are of the triple-negative subtype. Treatment is lacking for patients with this type of breast cancer, and their prognosis is poor . Thus, treatment for breast cancer has been a difficult issue.
Many patients seek natural, traditional treatments to alleviate or improve breast cancer and the side effects caused by treatment. Herbal therapy has been used for thousands of years, and there are several organisms that provide a source of anti-cancer drugs in nature. Several Chinese herbal medicines are effective against diseases, but most of the effects and mechanisms of action are not scientifically supported. The effect of Chinese herbal medicines on cancer has become a hot research topic. For instance, EGCG extracted from green tea inhibits the growth of pancreatic cancer cells . EGCG also induces MCF-7 cells towards p53-related apoptosis in breast cancer cells . Intake of EGCG extracted from green tea reduces the occurrence of head and neck cancer . Besides, huanglian increases the inhibition of cell cycle-related protein expression, leading to suppressed growth of cancer cells . The popular sporophore extract from Antrodia cinnamomea reduces the invasive ability of hepatoma cells by inhibiting the NF-κB signal transduction pathway . Betulin, isolated from H. syriacus , is a natural triterpene that has anti-cancer effects, but its mechanism of action remains unclear [10,11].
H. syriacus is found in tropical and subtropical areas. The flower, fruit, root, stem, and skin of H. syriacus all show pharmaceutical effects and have been widely used as medicinal treatment materials in Asia. The flower from H. syriacus is used for the treatment of dysentery, vaginal discharge, and hemorrhoids; the fruit is used as an expectorant and for cough and neurological headache; the skin has antipyretic, anthelmintic, antibacterial effects, and its oral administration is used for the treatment of dysentery and vaginal discharge, while external application is used for the treatment of eczema, psoriasis, and scabies [12,13]. In 1998, Yoo et al. discussed the components of H. syriacus skin in depth . However, there are few references discussing its anti-cancer effects. Only a study in 2008 by Cheng et al. showed that H. syriacus skin extract activated p53 and apoptosis-inducing factor (AIF), which induced apoptosis in human lung cancer cells .
In this study, fifteen H. syriacus skin extracts were screened, including seven crude extracts and eight pure compounds. After treating estrogen receptor (ER)-negative and triple-negative breast cancer cell lines with the extracts, functional assays were performed, which showed cell viability-inhibitory effects. In addition, triterpenoids (betulin and its derivatives) isolated from H. syriacus skin activated the signaling pathway regulated by p53 family genes, leading to the inhibition of breast cancer cell viability or even the induction of apoptosis. And those triterpenoids had no effect on normal breast cells. These findings provide an important basis for the use of those triterpenoids in the development of alternative therapies for breast cancer treatment.
Human breast cancer cell lines MDA-MB-231 and HBL-100 were originally obtained from American Type Culture Collection (ATCC, Manassas, VA). Non-tumorigenic human breast epithelial cell line H184B5F5/M10 was obtained from the Bioresource Collection and Research Center (BCRC, Taiwan). MDA-MB-231 and HBL-100 were maintained in Dulbecco’s Modified Eagle medium (DMEM) containing 10% fetal bovine serum, 1 μg/ml penicillin and 1 μg/ml streptomycin (Invitrogen) at 37°C in a 5% CO2 atmosphere. H184B5F5/M10 cells were grown in MEM-α with the same supplements and culture condition.
Plant material and compounds
The root bark of H. syriacus was obtained from Chien-Yuan Co., Taipei, Taiwan, in September 2009, and the plant was authenticated by Hang-Ching Lin from a voucher specimen (NDMCP no. 980901). All compounds for screening were offered by Professor Wen-Liang Chang, and the detailed isolating approaches of those compounds are described in reference .
Cell viability determined by MTT assay
Cells treated with the indicated concentrations of compounds were washed twice with phosphate buffered saline (PBS) and subjected to the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay to measure proliferation. In brief, 20 μl of 5 mg/ml MTT reagent was added to each well and incubated at 37°C for 3.5 h before reading absorbance at 570 nm. A570 was recorded at 0 h, 24 h, 48 h, and 72 h after treatment. Each condition was performed in six replicates. Cell morphology was visualized under the indicated conditions by using an Olympus CKX41 light microscope.
Wound healing assays were employed to evaluate the effects of those compounds on the cell migratory ability. Cells were plated in 6-cm dishes and cultured to >90% confluence. They were scraped with a p200 pipette tip (time 0), transferred to low-serum culture medium, and treated as indicated. The distances of migrating cells were measured from pictures (five fields) taken at 0h, 12h, and 24h, and the distance of each measurement was calculated by ImageJ (NIH, USA). Each experiment was independently repeated at least three times.
Western blot analysis
Treated cells were washed twice with PBS, then lysed in 200 μl of RIPA lysis buffer (Millipore, 50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitor (Roche). Thirty micrograms of protein from the supernatant was loaded on an SDS-polyacrylamide gel, followed by western blot analysis (antibody information is listed in Additional file 1: Table S2). The immuno-reactive bands were revealed by an ECL system (Millipore) then developed and quantified on a UVP BioSpectrum Imaging System. Each band was quantified using ImageJ. β-Actin used as internal (loading) control for relative quantitation.
Real-time PCR original data, western blot data and wound healing regions were recorded as continuous variables and analyzed with Student’s t-test. All the statistical analyses were performed using SPSS 16.0 and Excel 2010. All statistical tests and P values were two-sided. The level of significance was set at P < 0.05.
Real-time PCR and flow cytometry
Detail methods of RNA preparation, quantitative real-time PCR, and flow cytometry were described in Additional file 1.
Toxicity analysis of H. syriacus extracts on breast cancer cell lines
The results from the MTT assay showed that the inhibitory effects of K01, K02, K03, K04, and K06 on the cell viability of breast cancer cell lines were the greatest. However, they had non-significant effects on the cell viability of the non-tumorigenic human breast epithelial cell line H184B5F5/M10 (Additional file 1: Figure S5E). Compound structural analysis showed that K01, K02, K03, K04, and K06 were the derivatives of betulin (Additional file 1: Figure S1), but the mechanism of action of these compounds was unclear. Thus, we evaluated the biological effects of betulin and its derivatives on breast cancer cells.
Betulin and its derivatives induce morphology changes in breast cancer cell lines
Betulin and it derivatives induce breast cancer cell apoptosis
To examine the cell cycle and proportion of sub-G1 phase cells in breast cells after treatment with betulin or its derivatives, HBL-100 and H184B5F5/M10 cells were treated with 10 μg/mL of K02, K03, K04 or K06 for 48 h, stained with PI and subjected to flow cytometry. The cells treated with those triterpenoids showed a significant increase in the proportion of cells in sub-G1 phase compared to the DMSO control group. These results indicate that betulin and it derivatives induced apoptosis in breast cancer cells (Additional file 1: Figure S2). The compounds had a relatively lower toxicity to the non-tumorigenic human breast epithelial cell line H184B5F5/M10 (Additional file 1: Figure S5F).
HBL-100 cells treated with 10 μg/mL of K02, K03, K04 or K06 for 48 h were further double-stained with Annexin V/PI for flow cytometry to determine the toxic effects of betulin and its derivatives on breast cancer cells. The results showed that >50% (the sum of the first and fourth quadrant) of cells were apoptotic after K06 treatment, approximately 40% were apoptotic after K02 treatment, and approximately 25% of cells were apoptotic after K03 or K04 treatment. Overall, apoptosis was significantly increased in the drug-treated groups compared with DMSO control cells (2.06% apoptotic cells) (Additional file 1: Figure S3). And K02 and K06 possessed a greater ability to induce apoptosis than K03 and K04.
Betulin and it derivatives inhibit migration of breast cancer cells
Betulin and its derivatives induce apoptosis in breast cancer cells was related to TAp63
The H. syriacus skin extracts K02 and K06 induced apoptosis in MDA-MB231 cells. Betulin and betulinic acid can induce cancer cell death via intrinsic apoptotic pathways [17,18]. Furthermore, H. syriacus skin extracts activate p53 and AIF, leading to lung cancer cell apoptosis . After treating cells with 10 μg/mL of K02, K03, K04 or K06 for 12, 24, or 36 h, we performed real-time PCR to analyze the apoptosis-related genes BAX, NOXA, PERP, and PUMA, and the p63 isoforms ΔNp63 and TAp63. p63 is one member of the p53 tumor suppressor gene family, and it is highly similar to p53 in protein structure. Based on the sequence at the N-terminal end of the protein, p63 is classified into two isoforms, ΔNp63 and TAp63 [19,20]. ΔNp63 and TAp63 antagonize each other in the regulation of gene expression. For example, ΔNp63 inhibits TAp63-regulated p53 downstream gene expression [19,20] and promotes anti-apoptotic gene expression. After treating with K02 and K06 for 12 h, TAp63 was significantly increased at 24 h and slightly decreased at 36 h. The TAp63 antagonist ΔNp63 also increased at 12 h and dramatically decreased at 24 h or 36 h. In addition, most of the TAp63 downstream apoptotic genes, including BAX, NOXA, PUMA and PERP, increased over time (Additional file 1: Figure S4A and 4D). These results imply that K02 and K06 induced apoptotic gene expression is TAp63 associated in the MDA-MB-231 cell line. Although K03 and K04 treatment also increased TAp63 expression, no significant change was observed in ΔNp63 or downstream apoptotic genes (Additional file 1: Figure S4B and 4C). Therefore, in p53-mutated MDA-MB-231 breast cancer cells, K02 and K06 may induce TAp63 expression to compensate for parts of p53 function.
Real-time PCR was performed to analyze ΔNp63 and TAp63 RNA expression. After treatment with K02 or K06 for 12 h, TAp63 significantly increased at 24 h and slightly decreased at 36 h. ΔNp63 also increased at 12 h, but it lost significance or returned close to baseline at 24 h or 36 h. Although K03 and K04 treatment also increased TAp63 expression, ΔNp63 expression showed no significant changes. These results indicate that in the MDA-MB-231 cell, K02 and K06 induced apoptotic gene expression in a TAp63-associated manner. Although K03 and K04 treatment increased TAp63 expression, no increase in downstream gene expression was observed (Additional file 1: Figure S4). Thus, in p53-mutated MDA-MB-231 breast cancer cells, K02 and K06 may induce TAp63 expression to compensate parts of p53 function. In the non-tumorigenic human breast epithelial cell, H184B5F5/M10, the expression of BAX, NOXA, PUMA and PERP showed no change with K02, K03, K04 or K06 treatment, whereas TAp63 decreased with treatment time and ΔNp63 expression fluctuated (Additional file 1: Figure S5A-D).
Accumulating evidence demonstrates that induction of apoptosis in cancer cells is the major effect of chemotherapy [9,15]. In this study, betulin and its derivatives also induced human breast cancer cell apoptosis, and there were different susceptibilities between the cell lines. For instance, betulin (K02) and betulinic acid (K06) led to higher apoptosis in HBL-100 than MDA-MB-231 cells (Figure 1C and 1D). Dysregulated apoptosis is typically observed in cancer cells; however, betulin derivatives regulated different apoptotic proteins in different cancer types [10,11,17]. In the present study, betulin (K02) and betulinic acid (K06) had different IC50 values between HBL-100 and MDA-MB-231 cells (Figure 1A and 1B). Because MDA-MB-231 is a p53-mutant cell line and HBL-100 is a p53-wild-type cell line, we found that MDA-MB-231 cells induced the tumor suppressor TAp63 in a compensatory manner. TAp63 is a highly conserved member of the p53 family that is structurally similar to p53; therefore, it was able to induce apoptosis by activating p53 downstream target genes, including BAX, NOXA, PUMA, and PERP (Additional file 1: Figure S4) [21-23]. TAp63 can also induce p21 expression and has been associated with cell cycle arrest and apoptosis [24,25].
In addition, K03 and K04 betulin derivatives induced a lower level of apoptosis than K02 and K06 (Additional file 1: Figure S2); however, K03 and K04 caused G2/M arrest, as shown by flow cytometry. Furthermore, K03 and K04 repressed cell migration in wound healing assays (Figure 3).
Basal-like breast cancer is generally triple-negative (ER-negative, PR-negative, and Her2/neu-negative), with a similar gene expression profile to myoepithelial cells . However, it remains difficult to clearly distinguish basal-like breast cancer from triple-negative breast cancer . Clinically, triple-negative breast cancer possesses higher invasiveness, more distal metastasis and poor prognosis . The BRCA1 tumor suppressor participates in DNA repair and is often mutated in triple-negative breast cancers . The basal-like breast cancer gene expression profile is also similar to BRCA1-mutated breast cancer, as shown by microarray  and immunohistochemical analysis , particularly in early-onset or familial breast cancer, and it is usually accompanied by a p53 mutation. Several studies have addressed the association between p53 and anthracycline treatment [32,33], and p53 functions as a prognostic indicator of triple-negative breast cancer therapeutic efficacy . We employed two triple-negative breast cancer cell lines, MDA-MB-231 and HBL100 , to investigate the regulatory mechanism of H. syriacus extracts on cell proliferation and apoptosis. Therefore, H. syriacus extracts or betulin and its derivatives may function as potential adjuvant treatments in p53-mutant cancers [36,37].
In this study, we have described four major findings: (1) the natural compound betulin (K02) and its derivatives (K03, K04, K06) induced human breast cancer cell apoptosis and inhibited cell proliferation; (2) K02 (betulin) and K06 (betulinic acid) induced apoptotic protein expression, including BAX, NOXA, PUMA and PERP, and also increased caspase-3 cleavage as well reduced the anti-apoptotic gene Bcl-x in MDA-MB-231 and HBL-100 cells; (3) K02 and K06 induced TAp63 in the p53-mutant MDA-MB-231 cell line, leading top53-related apoptosis; (4) betulin and its derivatives induced p21 activation and promoted cell cycle arrest.
This work is supported by grants from the Ministry of Science and Technology (MOST 103-2320-B-016-013- and MOST 103-2320-B-016-019-), the National Science Council (NSC102-2320-B-010), the Tri-Service General Hospital (TSGH-C100-135, TSGH-C101-003, TSGH-C101-011, TSGH-C102-070, TSGH-C102-062, TSGH-C102-003, TSGH-C103-004, TSGH-C103-101, TSGH-C103-064, TSGH-C104-072, and TSGH-C104-210), the Cardinal Tien Hospital (CTH-101-1-2A18 and CTH-103-1-2C02), Chi-Mei Medicine Center (CMNDMC-10213 and CMNDMC-10313), and Ministry of Health and Welfare (10311). All compounds for screening were kindly provided by Professor Wen-Liang Chang (School of Pharmacy, National Defense Medical Center, Taipei, Taiwan).
- Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site.Google Scholar
- Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631–43.PubMedGoogle Scholar
- Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8(3):235–44.PubMedGoogle Scholar
- Vu HA, Beppu Y, Chi HT, Sasaki K, Yamamoto H, Xinh PT, et al. Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. J Biomed Biotechnol. 2010;2010:290516.PubMedGoogle Scholar
- Alshatwi AA. Catechin hydrate suppresses MCF-7 proliferation through TP53/Caspase-mediated apoptosis. J Exp Clin Cancer Res. 2010;29:167.PubMedPubMed CentralGoogle Scholar
- Masuda M, Wakasaki T, Toh S, Shimizu M, Adachi S. Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG-The Role of EGFR Signaling and "Lipid Raft". J Oncol. 2011;2011:540148.PubMedPubMed CentralGoogle Scholar
- Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK. Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol. 2000;58(6):1287–93.PubMedGoogle Scholar
- Hsu YL, Kuo PL, Cho CY, Ni WC, Tzeng TF, Ng LT, et al. Antrodia cinnamomea fruiting bodies extract suppresses the invasive potential of human liver cancer cell line PLC/PRF/5 through inhibition of nuclear factor kappaB pathway. Food Chem Toxicol. 2007;45(7):1249–57.PubMedGoogle Scholar
- Zhang EJ, Kang QS, Zhang Z. Chemical constituents from the bark of Hibiscus syriacus L. Zhongguo Zhong Yao Za Zhi. 1993;18(1):37. –8, 63.PubMedGoogle Scholar
- Rzeski W, Stepulak A, Szymański M, Juszczak M, Grabarska A, Sifringer M, et al. Betulin elicits anti-cancer effects in tumour primary cultures and cell lines in vitro. Basic Clin Pharmacol Toxicol. 2009;105(6):425–32.PubMedGoogle Scholar
- Pyo JS, Roh SH, Kim DK, Lee JG, Lee YY, Hong SS, et al. Anti-cancer effect of Betulin on a human lung cancer cell line: a pharmacoproteomic approach using 2D-SDS-PAGE coupled with nano-HPLC tandem Mass Spectrometry. Planta Med. 2009;75(2):127–31.PubMedGoogle Scholar
- Huang KC. The Pharmacology of Chinese Herbs. 2nd ed. New York: CRC Press; 1999. p. 242.Google Scholar
- Hsu HY, Chen YP, Shen SJ, Hsu CS, Chen CC, Chang HC. Oriental materia medica: a concise guide. Taiwan: Oriental Healing Arts Institute; 1986. p. 503–4.Google Scholar
- Yoo ID, Yun BS, Lee IK, Ryoo IJ, Choung DH, Han KH. Three naphthalenes from root bark of Hibiscus syriacus. Phytochemistry. 1998;47(5):799–802.PubMedGoogle Scholar
- Cheng YL, Lee SC, Harn HJ, Huang HC, Chang WL. The extract of Hibiscus syriacus inducing apoptosis by activating p53 and AIF in human lung cancer cells. Am J Chin Med. 2008;36(1):171–84.PubMedGoogle Scholar
- Shi LS, Wu CH, Yang TC, Yao CW, Lin HC, Chang WL. Cytotoxic effect of triterpenoids from the root bark of Hibiscus syriacus. Fitoterapia. 2014;97:184–91.PubMedGoogle Scholar
- Li Y, He K, Huang Y, Zheng D, Gao C, Cui L, et al. Betulin induces mitochondrial cytochrome c release associated apoptosis in human cancer cells. Mol Carcinog. 2010;49(7):630–40.PubMedGoogle Scholar
- Eichenmüller M, Hemmerlein B, von Schweinitz D, Kappler R. Betulinic acid induces apoptosis and inhibits hedgehog signalling in rhabdomyosarcoma. Br J Cancer. 2010;103(1):43–51.PubMedPubMed CentralGoogle Scholar
- Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398(6729):714–8.PubMedGoogle Scholar
- Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;1(3):199–207.PubMedGoogle Scholar
- Ihrie RA, Marques MR, Nguyen BT, Horner JS, Papazoglu C, Bronson RT, et al. Perp is a p63-regulated gene essential for epithelial integrity. Cell. 2005;120(6):843–56.PubMedGoogle Scholar
- Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol. 2003;14(2):214–9.PubMedGoogle Scholar
- Shibue T, Suzuki S, Okamoto H, Yoshida H, Ohba Y, Takaoka A, et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J. 2006;25(20):4952–62.PubMedPubMed CentralGoogle Scholar
- Attardi LD. The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models. Mutat Res. 2005;569(1–2):145–57.PubMedGoogle Scholar
- Attardi LD, DePinho RA. Conquering the complexity of p53. Nat Genet. 2004;36(1):7–8.PubMedGoogle Scholar
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.PubMedGoogle Scholar
- Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer–current status and future directions. Ann Oncol. 2009;20(12):1913–27.PubMedGoogle Scholar
- Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.PubMedGoogle Scholar
- Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310–8.PubMedGoogle Scholar
- Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.PubMedPubMed CentralGoogle Scholar
- Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64(3):830–5.PubMedGoogle Scholar
- Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, et al. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 2000;60(8):2155–62.PubMedGoogle Scholar
- Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 2001;61(6):2505–12.PubMedGoogle Scholar
- Chae BJ, Bae JS, Lee A, Park WC, Seo YJ, Song BJ, et al. p53 as a specific prognostic factor in triple-negative breast cancer. Jpn J Clin Oncol. 2009;39(4):217–24.PubMedGoogle Scholar
- Davison Z, de Blacquière GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia. 2011;13(6):504–15.PubMedPubMed CentralGoogle Scholar
- Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat. 2005;25(1):6–17.PubMedGoogle Scholar
- Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1(3):233–40.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.